Physician profile
Amy Lee
NPI 1669964912
$3,483.20
in general payments reported to CMS, 2019-2025
27 companies · $985 in 2025
The $985 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $493 · 2023: $773 · 2024: $616 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.49 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.49 | 2021-2025 | |
| Incyte Corporation | $334.17 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $269.46 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $243.58 | 2023-2025 | Zoryve |
| Genzyme Corporation | $192.83 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $165.64 | 2022-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $161.11 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $155.70 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $149.32 | 2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $124.98 | 2023 | Linzess |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.84 | 2021-2025 | Jublia |
| E.R. Squibb & Sons, L.L.C. | $111.64 | 2023-2024 | Sotyktu |
| Ucb, INC. | $99.85 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $78.12 | 2024-2025 | |
| Epi Health, LLC | $68.94 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.60 | 2023 | |
| Boston Scientific Corporation | $46.68 | 2025 | Wavewriter Alpha Prime 16 |
| Organon LLC | $46.67 | 2025 | Vtama |
| Dermavant Sciences, INC. | $44.64 | 2022-2023 | Vtama |
| Amgen INC. | $31.97 | 2025 | Otezla |
| Lilly USA, LLC | $30.45 | 2025 | Ebglyss |
| Vyne Pharmaceuticals INC. | $27.34 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.18 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $22.03 | 2023-2025 | |
| Dermira, INC. | $22.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.71 | 2023 | Spevigo |
| Biofrontera INC. | $18.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.